Wire · opportunities
Nimbus Therapeutics to Present New Preclinical Data on Selective SIK2 Inhibition in ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 November 2026 · Fusion42 review
Nimbus Therapeutics revealed new preclinical data indicating that selective inhibition of salt-inducible kinase 2 (SIK2) significantly reduces inflammation and bone erosion in rheumatoid arthritis models, showing comparable efficacy to existing treatments etanercept and upadacitinib. This positions selective SIK2 inhibitors as a promising oral therapy targeting dual mechanisms in RA and other immune-mediated inflammatory diseases.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now explore a new oral treatment approach targeting both inflammation and bone loss in rheumatoid arthritis. This dual-action inhibitor opens a fresh route in immune disease therapies that might outpace current drugs on patient impact.
◆ Coverage
1 source · 5 Nov 2026
◆ Related on Wire
◆ Topics